CA3246681A1 - PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES - Google Patents
PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVESInfo
- Publication number
- CA3246681A1 CA3246681A1 CA3246681A CA3246681A CA3246681A1 CA 3246681 A1 CA3246681 A1 CA 3246681A1 CA 3246681 A CA3246681 A CA 3246681A CA 3246681 A CA3246681 A CA 3246681A CA 3246681 A1 CA3246681 A1 CA 3246681A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pyrido
- amino
- pyridazin
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/704,983 US11618751B1 (en) | 2022-03-25 | 2022-03-25 | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US17/704,983 | 2022-03-25 | ||
| US202263420930P | 2022-10-31 | 2022-10-31 | |
| US63/420,930 | 2022-10-31 | ||
| US202363443874P | 2023-02-07 | 2023-02-07 | |
| US63/443,874 | 2023-02-07 | ||
| PCT/US2023/064967 WO2023183943A1 (en) | 2022-03-25 | 2023-03-24 | Pyrido-[3,4-d]pyridazine amine derivatives useful as nlrp3 derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3246681A1 true CA3246681A1 (en) | 2023-09-28 |
Family
ID=86329581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3246681A Pending CA3246681A1 (en) | 2022-03-25 | 2023-03-24 | PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP4499638A1 (https=) |
| JP (1) | JP2025510414A (https=) |
| KR (1) | KR20250005125A (https=) |
| CN (1) | CN119137121A (https=) |
| AU (1) | AU2023238121A1 (https=) |
| CA (1) | CA3246681A1 (https=) |
| CL (1) | CL2024002855A1 (https=) |
| CO (1) | CO2024013702A2 (https=) |
| IL (1) | IL315842A (https=) |
| MX (1) | MX2024011697A (https=) |
| PE (1) | PE20250605A1 (https=) |
| TW (1) | TW202345836A (https=) |
| WO (1) | WO2023183943A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| TW202313577A (zh) | 2021-06-04 | 2023-04-01 | 瑞士商赫孚孟拉羅股份公司 | 新穎化合物 |
| US12331048B2 (en) * | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| KR20250106322A (ko) * | 2022-12-28 | 2025-07-09 | 장춘 진사이언스 파마슈티컬 씨오., 엘티디. | 피리다진계 nlrp3 억제제 화합물, 약학 조성물 및 이의 제조 방법과 용도 |
| WO2025059481A1 (en) | 2023-09-13 | 2025-03-20 | Ventus Therapeutics U.S., Inc. | Solid forms of an nlrp3 inhibitor and uses thereof |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US11618751B1 (en) * | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) * | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| CR20240093A (es) * | 2021-08-25 | 2024-05-23 | Ptc Therapeutics Inc | Inhibidores de NLRP3 |
-
2023
- 2023-03-24 CA CA3246681A patent/CA3246681A1/en active Pending
- 2023-03-24 PE PE2024002059A patent/PE20250605A1/es unknown
- 2023-03-24 WO PCT/US2023/064967 patent/WO2023183943A1/en not_active Ceased
- 2023-03-24 JP JP2025502799A patent/JP2025510414A/ja active Pending
- 2023-03-24 KR KR1020247034096A patent/KR20250005125A/ko active Pending
- 2023-03-24 EP EP23722227.8A patent/EP4499638A1/en active Pending
- 2023-03-24 CN CN202380037553.1A patent/CN119137121A/zh active Pending
- 2023-03-24 TW TW112111280A patent/TW202345836A/zh unknown
- 2023-03-24 AU AU2023238121A patent/AU2023238121A1/en active Pending
- 2023-03-24 IL IL315842A patent/IL315842A/en unknown
-
2024
- 2024-09-24 CL CL2024002855A patent/CL2024002855A1/es unknown
- 2024-09-24 MX MX2024011697A patent/MX2024011697A/es unknown
- 2024-10-10 CO CONC2024/0013702A patent/CO2024013702A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024011697A (es) | 2024-11-08 |
| JP2025510414A (ja) | 2025-04-14 |
| IL315842A (en) | 2024-11-01 |
| PE20250605A1 (es) | 2025-02-26 |
| CN119137121A (zh) | 2024-12-13 |
| WO2023183943A1 (en) | 2023-09-28 |
| KR20250005125A (ko) | 2025-01-09 |
| TW202345836A (zh) | 2023-12-01 |
| CO2024013702A2 (es) | 2024-11-08 |
| CL2024002855A1 (es) | 2025-02-14 |
| AU2023238121A1 (en) | 2024-10-10 |
| EP4499638A1 (en) | 2025-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023263450B2 (en) | Pyridazine compounds for inhibiting nlrp3 | |
| CA3246681A1 (en) | PYRIDO-[3,4-D]PYRIDAZINE AMINE DERIVATIVES USEFUL AS NLRP3 DERIVATIVES | |
| CA2971024C (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| US12398136B2 (en) | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors | |
| EP4037677B1 (en) | Antagonists of the muscarinic acetylcholine receptor m4 | |
| WO2014146494A1 (zh) | β-氨基羰基类化合物、其制备方法、药物组合物及其用途 | |
| TWI860797B (zh) | 新穎acc抑制劑 | |
| CN105153154A (zh) | Btk抑制剂及其用途 | |
| JP7748560B2 (ja) | ピラゾロ縮合環化合物及びその使用 | |
| JP2010513383A (ja) | セロトニン、ドーパミンおよびノルエピネフリン再取り込み阻害剤としてのアザビサイクリック化合物 | |
| EA051595B1 (ru) | Соединения пиридазина для ингибирования nlrp3 | |
| CN119490507A (zh) | 一种新型激酶抑制剂 | |
| WO2022117012A1 (zh) | 螺环jak抑制剂、含其的药物组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT Effective date: 20240924 |
|
| A15 | Pct application entered into the national or regional phase |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241008 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241008 |
|
| A00 | Application filed |
Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET Effective date: 20241106 |
|
| P18 | Priority claim added or amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241106 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250213 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250307 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250307 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260309 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260309 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260416 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260416 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260416 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260417 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260420 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260420 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260423 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260423 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260423 |